10-Q: Amedisys Reports Mixed Q2 Results Amidst Ongoing UnitedHealth Merger Litigation and Proposed Medicare Payment Cuts

Amedisys, a leading home health and hospice provider, reported increased net service revenue but a decline in three-month net income due to higher merger-related expenses, while six-month net income surged from a one-time gain, as its proposed merger with UnitedHealth Group faces continued antitrust challenges and a significant proposed Medicare payment reduction looms.

Summary

• Net service revenue increased to $621.9 million for the three months ended June 30, 2025, up from $591.2 million in the prior year, and to $1,216.6 million for the six months, up from $1,162.6 million.
• Operating income decreased to $45.6 million for the three months, down from $52.2 million, but increased to $88.9 million for the six months, up from $83.8 million.
• Net income attributable to Amedisys, Inc. was $28.1 million ($0.84 diluted EPS) for the three months, compared to $32.3 million ($0.98 diluted EPS) in the prior year.
• Net income attributable to Amedisys, Inc. was $89.1 million ($2.68 diluted EPS) for the six months, significantly up from $46.7 million ($1.42 diluted EPS) in the prior year, primarily due to a $48.1 million gain on an equity method investment.
• Merger-related expenses totaled $26.3 million for the three months and $43.0 million for the six months, compared to $11.9 million and $32.6 million respectively in the prior year periods.
• Excluding merger-related expenses, operating income increased by $7 million for the three-month period and $15 million for the six-month period.
• The proposed merger with UnitedHealth Group is ongoing, with a DOJ lawsuit pending and a tentative trial date set for October 27, 2025, or potentially February 9, 2026.
• A waiver was executed on December 26, 2024, extending the merger termination right until December 31, 2025, or 10 business days after a final DOJ order, and increasing the regulatory break fee to $275 million.
• Divestiture agreements were signed on April 30, 2025, with BrightSpring Health Services and The Pennant Group for certain home health and hospice care centers, subject to DOJ approval and merger consummation.
• CMS proposed a 6.4% decrease in Medicare home health payments for Calendar Year 2026, a significant potential headwind.
• Cash and cash equivalents increased to $337.3 million as of June 30, 2025, from $303.2 million at December 31, 2024.
• Days revenue outstanding improved to 40.9 days at June 30, 2025, from 43.0 days at December 31, 2024, and 52.1 days at June 30, 2024, with cash collections as a percentage of revenue at 101% for the six-month period.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company shows strong operational growth in its core segments (excluding merger costs) and improved liquidity, the significant proposed Medicare home health payment cut for CY 2026 and the ongoing, uncertain, and costly merger litigation with the DOJ introduce substantial future headwinds and risks that temper positive financial performance.

Positives

• Net service revenue increased by $30.7 million (5.2%) for the three-month period and $54 million (4.6%) for the six-month period year-over-year.
• Excluding merger-related expenses, operating income increased by $7 million for the three-month period and $15 million for the six-month period, indicating underlying operational improvement.
• Six-month net income attributable to Amedisys, Inc. significantly increased by $42.4 million, largely driven by a $48.1 million gain on an equity method investment.
• Home Health segment reported 6% same store total volume growth for both three and six-month periods.
• Hospice segment showed 6% same store Medicare revenue growth for the three-month period and 5% for the six-month period, with a 1% increase in average daily census.
• High Acuity Care segment achieved its highest total admissions volume since inception, with 29% growth for the three-month period and 30% for the six-month period.
• High Acuity Care segment's operating loss improved from $(9.0) million to $(7.2) million for the six-month period.
• Cash and cash equivalents increased to $337.3 million, and $508.0 million remains available under the $550.0 million Revolving Credit Facility, indicating strong liquidity.
• Days revenue outstanding improved to 40.9 days, reflecting better collection efficiency.
• Weighted average interest rate for the Term Loan Facility decreased to 6.0% for the three and six-month periods ended June 30, 2025, from 7.3% in the prior year periods.

Negatives

• Net income attributable to Amedisys, Inc. decreased by $4.2 million for the three-month period, primarily due to a $14.4 million increase in merger-related expenses.
• Basic and diluted earnings per common share decreased for the three-month period.
• The High Acuity Care segment continues to report an operating loss, which increased for the three-month period due to lower savings on a risk-based palliative care contract and severance costs.
• CMS proposed a significant 6.4% decrease in Medicare home health payments for Calendar Year 2026, which includes a permanent adjustment of -3.7% and a temporary adjustment of -4.6% related to prior overpayments.
• The ongoing DOJ lawsuit against the proposed merger with UnitedHealth Group creates significant uncertainty and incurs substantial legal and merger-related expenses.
• The company recorded a non-cash impairment charge of $0.9 million on a cost method investment during the three-month period ended June 30, 2025.
• The company expects inflation to continue impacting operations, particularly labor and healthcare costs, despite partial mitigation by rate increases and reorganization initiatives.

Risks

• Disruption from the proposed merger with UnitedHealth Group on patient, payor, provider, referral source, supplier, management, and employee relationships.
• The occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on anticipated terms or by the end of the Waiver Period.
• The risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, not obtained, or obtained subject to unanticipated conditions.
• The failure of the conditions to the proposed merger to be satisfied.
• The costs related to the proposed transaction, including significant additional merger-related expenses.
• The diversion of management time on merger-related issues.
• The risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances, including a potential $106 million reimbursement to UnitedHealth Group and an additional $125 million fee to UnitedHealth Group.
• Reputational risk related to the proposed merger.
• The risk of litigation or regulatory action related to the proposed merger, including the ongoing DOJ Action.
• Changes in Medicare and other medical payment levels, including the proposed 6.4% decrease in Medicare home health payments for CY 2026.
• Changes in payments and covered services by federal and state governments.
• Future cost containment initiatives undertaken by third-party payors.
• Changes in the episodic versus non-episodic mix of payors, the case mix of patients, and payment methodologies.
• Staffing shortages driven by the competitive labor market and the ability to attract and retain qualified personnel.
• Competition in the healthcare industry.
• The ability to maintain or establish new patient referral sources.
• Changes in or failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis.
• Changes in estimates and judgments associated with critical accounting policies.
• The ability to consistently provide high-quality care and keep patients and employees safe.
• Access to financing, ability to meet debt service requirements, and comply with covenants in debt agreements.
• Business disruptions due to natural or man-made disasters, climate change, acts of terrorism, widespread protests, or civil unrest.
• The ability to open care centers, acquire additional care centers, and integrate and operate these care centers effectively.
• The ability to realize the anticipated benefits of acquisitions, investments, and joint ventures.
• The ability to integrate, manage, and keep information systems secure.
• The impact of inflation on labor and healthcare costs.
• The impact of new or increased tariffs.
• Uncertainty around, and disruption from, new and emerging technologies, including the adoption and utilization of artificial intelligence ('AI') and generative AI.
• Litigation relating to the Company, including ongoing third-party audits and appeals related to alleged Medicare overpayments.

Future Outlook

The company expects to incur significant additional merger-related expenses until the closing of the proposed merger with UnitedHealth Group. The High Acuity Care segment is expected to continue generating operating losses but anticipates improvement by leveraging its operating structure. Capital expenditures and investments in technology assets for 2025 are projected to be approximately $4 million to $6 million, excluding future acquisitions. The company believes it has sufficient liquidity to fund operations, capital requirements, and debt service for the next twelve months and beyond. The company is actively engaging with industry advocates and lobbying firms to provide comments to CMS regarding the proposed 6.4% decrease in Medicare home health payments for Calendar Year 2026.

Management Comments

• Believe the plaintiffs' claims in the DOJ Action are without merit and intend to vigorously defend against such claims.
• Expect the impact of the final rule for hospice payment rates for fiscal year 2025 to be in line with the 2.9% increase.
• Expect the impact of the proposed rule for hospice payment rates for fiscal year 2026 to be in line with the 2.4% increase.
• Expect the impact of the final rule for Medicare home health providers for Calendar Year 2025 to be in line with the 0.5% increase.
• Expect the impact of the proposed rule for Medicare home health providers for Calendar Year 2026 to be in line with the 6.4% decrease.
• Partnering with industry advocates, lobbying firms, and others to share comments with CMS on the proposed home health rule.
• Expect the high acuity care segment to continue to generate operating losses; however, also expect improvement as the operating structure is leveraged.
• Expect inflation to continue to impact operations in 2025, with impacts partially mitigated by rate increases and reorganization initiatives.
• Believe there will be sufficient liquidity to fund operations, capital requirements, and debt service requirements for the next twelve months and beyond.

Industry Context

The home health and hospice industry is heavily influenced by Medicare reimbursement rates and regulatory changes. Amedisys's performance reflects these dynamics, with Medicare accounting for approximately 68% of its consolidated net service revenue. The proposed 6.4% cut to Medicare home health payments for CY 2026, if finalized, represents a significant industry-wide challenge, potentially impacting profitability and operational strategies for all providers. The ongoing consolidation trend, exemplified by the proposed UnitedHealth Group merger and the required divestitures, highlights the competitive and evolving landscape, driven by efforts to achieve scale and integrate care models. The increasing focus on high acuity care at home also indicates a broader shift towards value-based care and cost containment within the healthcare system.

Comparison to Industry Standards

• The proposed 6.4% decrease in Medicare home health payments for CY 2026 is a substantial reduction that could put pressure on profit margins across the home health sector, potentially impacting comparable companies like LHC Group (now part of Optum/UnitedHealth Group) and Encompass Health's home health segment (now Enhabit Home Health & Hospice).
• Amedisys's 6% same-store home health volume growth and 1% hospice average daily census growth indicate a healthy operational performance relative to a challenging regulatory environment, where some competitors might struggle to maintain or grow volumes amidst staffing shortages and reimbursement pressures.
• The company's ability to improve its days revenue outstanding to 40.9 days, especially after the Change Healthcare outage, demonstrates strong revenue cycle management compared to industry averages, which can vary but often aim for under 50 days for efficient collection.
• The divestiture agreements with BrightSpring Health Services and The Pennant Group are specific to the antitrust requirements of the UnitedHealth Group merger, reflecting a common strategy in large healthcare mergers to address regulatory concerns by shedding overlapping assets. This is comparable to divestitures seen in other large healthcare consolidations to gain regulatory approval.

Management Changes

Corporate Governance

Legal Proceedings

• U.S. Department of Justice (DOJ) and attorneys general of Maryland, Illinois, New Jersey, and New York filed a lawsuit (DOJ Action) against Amedisys and UnitedHealth Group on November 12, 2024, alleging the proposed merger would violate Section 7 of the Clayton Act and that Amedisys committed violations of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).
• The DOJ Action remains pending, with a tentative trial start date of October 27, 2025, or potentially February 9, 2026, and the HSR Act count stayed until the resolution of the Clayton Act count.
• Ongoing third-party audits by various governmental programs (RACs, ZPICs, UPICs, PSCs, MICs, SMRCs, CERTs, OIG) to identify potential improper payments.
• Appeal pending with the Medicare Appeals Council regarding a $5.7 million Medicare payment withholding (including interest) for a Florence, South Carolina hospice subsidiary related to an alleged overpayment from 2008-2010; the company has a $2.8 million indemnity receivable from prior owners.
• Repayments totaling $34.3 million for Lakeland Care Centers and $3.7 million for Clearwater Care Center were made in 2022 due to statistical extrapolations by SafeGuard Services, L.L.C. (ZPIC); the company expects to be indemnified by prior owners for approximately $10.9 million.

Related Party Transactions

• Incurred costs of approximately $2.7 million from January 1, 2025, through March 17, 2025, for usage of Medalogix's analytics platforms, prior to its combination into a new entity.
• Incurred costs of approximately $4.5 million during the three-month period ended June 30, 2025, and $5.1 million from March 18, 2025, through June 30, 2025, for usage of platforms from the newly formed combined entity (including Medalogix and a healthcare referral and workflow management company).
• Incurred costs of approximately $0.6 million during the three-month period ended June 30, 2025, and $1.4 million during the six-month period ended June 30, 2025, for usage of services from a technology-enabled clinician sourcing application in which the company has a cost method investment.

Stakeholder Impact

• Shareholders face uncertainty regarding the proposed merger with UnitedHealth Group, including potential delays, termination fees, and the final cash consideration of $101 per share.
• Employees may experience disruption and diversion of management time due to merger-related issues, and potential changes in employment if divestitures or the merger are completed.
• Patients and referral sources could be impacted by potential disruptions to relationships and services due to the merger and divestitures.
• Payors and providers may see changes in relationships and payment methodologies depending on the outcome of the merger and regulatory changes.
• Creditors are affected by the extension of the Credit Facility maturity date and the company's continued compliance with debt covenants, indicating stable financial health for debt servicing.
• The proposed 6.4% Medicare home health payment cut for CY 2026 could negatively impact the company's financial performance, potentially affecting its ability to invest in services or staff, which could indirectly affect patients and employees.

Next Steps

• Vigorously defend against the DOJ Action lawsuit regarding the proposed merger with UnitedHealth Group.
• Await the U.S. District Court for the District of Maryland's final determination on the merger trial date in late August 2025.
• Continue ongoing discussions with the DOJ regarding the scope of care centers to be divested under the BrightSpring and Pennant Purchase Agreements.
• Partner with industry advocates and lobbying firms to share comments with CMS on the proposed 6.4% decrease in Medicare home health payments for Calendar Year 2026.
• Continue winding down operations of one consolidated joint venture.
• Allyson Guidroz's 10b5-1 trading plan for up to 4,774 shares will commence with the first trade no earlier than August 18, 2025.

Key Dates

Recommendation

While Amedisys demonstrated solid underlying operational performance with revenue growth and improved operating income (excluding merger costs), and strong liquidity, the stock's immediate future is heavily overshadowed by two major uncertainties: the ongoing, costly, and uncertain DOJ antitrust lawsuit against its proposed merger with UnitedHealth Group, and the significant proposed 6.4% cut to Medicare home health payments for Calendar Year 2026. The one-time gain on an equity investment boosted six-month net income but is not indicative of recurring profitability. Investors should hold, awaiting clarity on the merger's outcome and the finalization of Medicare payment rates, as these factors will significantly influence future earnings and valuation.

Keywords

Home Health, Hospice, High Acuity Care, Medicare, Healthcare Services, Merger, UnitedHealth Group, DOJ Lawsuit, Antitrust, SEC Filing, 10-Q, Financial Results, Patient-Driven Groupings Model (PDGM), CMS Payment Updates, Healthcare Regulation, Divestiture, Liquidity, Earnings